FDA Gives Go-Ahead to Type 1 Drug in Development

Provention Bio has announced that the FDA’s advisory committee voted 10-7 that the benefits outweigh the risks of their drug candidate teplizumab, which is designed to delay the development of type 1 diabetes. The committee based its decision on safety and efficacy data from TN-10 Study in which a single 14-day course of teplizumab delayed insulin-dependent diabetes by a median of at least two years in presymptomatic patients. Read more

Posted in Type I Drugs